34
Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int
J Cancer 129:433–439
- Stanley MA, Winder DM, Sterling JC, Goon PK (2012) HPV infection, anal intra-epithelial
neoplasia (AIN) and anal cancer: current issues. BMC Cancer 12:398
- De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S (2009) Prevalence
and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of
the vulva, vagina and anus: a meta-analysis. Int J Cancer 124:1626–1636
- van Seters M, van Beurden M, de Craen AJ (2005) Is the assumed natural history of vulvar
intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published
patients. Gynecol Oncol 97:645–651
- Orth G (2010) Genetics and susceptibility to human papillomaviruses: epidermodysplasia ver-
ruciformis, a disease model. Bull Acad Natl Med 194:923–940. discussion 941
- Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M (2009) The EVER proteins as a natural
barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus
infections. Microbiol Mol Biol Rev: MMBR 73:348–370
- Armstrong EP (2010) Prophylaxis of cervical cancer and related cervical disease: a review of
the cost-effectiveness of vaccination against oncogenic HPV types. J Manage Care Pharm:
JMCP 16:217–230
- Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
New Engl J Med 356:1915–1927
- Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague
X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A,
Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T,
Descamps D, Struyf F, Lehtinen M, Dubin G (2009) Efficacy of human papillomavirus (HPV)-
16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic
HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Lancet (London, England) 374:301–314
- Hariri S, Markowitz LE, Dunne EF, Unger ER (2013) Population impact of HPV vaccines:
summary of early evidence. J Adolesc Health: Off Publ Soc Adolesc Med 53:679–682
- Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ (2013)
Genital warts in young Australians five years into national human papillomavirus vaccination
programme: national surveillance data. BMJ (Clin Res Ed) 346:f2032
- Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz
LE (2015) Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccina-
tion recommendations of the advisory committee on immunization practices. MMWR Morb
Mortal Wkly Rep 64:300–304
- Nigam A, Saxena P, Acharya AS, Mishra A, Batra S (2014) HPV Vaccination in India: Critical
Appraisal. ISRN Obstet Gynecol 2014:394595
- Tahamtan A, Ghaemi A, Gorji A, Kalhor HR, Sajadian A, Tabarraei A, Moradi A, Atyabi F,
Kelishadi M (2014) Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based
nanodelivery systems. J Biomed Sci 21:69
- McNamara M, Batur P, Walsh JM, Johnson KM (2016) HPV update: vaccination, screening,
and associated disease. J Gen Intern Med 31:1360–1366
- Grce M (2009) Primary and secondary prevention of cervical cancer. Expert Rev Mol Diagn
9:851–857
Y. Li and C. Xu
